IRIS UniCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.502
EU - Europa 3.492
AS - Asia 2.776
SA - Sud America 511
Continente sconosciuto - Info sul continente non disponibili 121
AF - Africa 81
OC - Oceania 7
Totale 10.490
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.357
SG - Singapore 1.329
DE - Germania 815
NL - Olanda 737
IT - Italia 708
CN - Cina 543
BR - Brasile 419
SE - Svezia 340
VN - Vietnam 256
FR - Francia 214
IE - Irlanda 139
GB - Regno Unito 130
IN - India 103
JP - Giappone 86
HK - Hong Kong 85
CA - Canada 75
FI - Finlandia 73
ID - Indonesia 68
RU - Federazione Russa 68
BD - Bangladesh 65
TR - Turchia 45
PL - Polonia 44
MX - Messico 39
ES - Italia 38
KR - Corea 37
AR - Argentina 35
UA - Ucraina 32
IQ - Iraq 26
ZA - Sudafrica 24
AT - Austria 23
PK - Pakistan 21
CZ - Repubblica Ceca 17
CO - Colombia 16
BE - Belgio 14
CH - Svizzera 14
EC - Ecuador 14
IR - Iran 14
EG - Egitto 13
MK - Macedonia 13
AE - Emirati Arabi Uniti 12
SA - Arabia Saudita 12
CI - Costa d'Avorio 11
IL - Israele 11
LT - Lituania 11
RS - Serbia 11
PH - Filippine 10
VE - Venezuela 9
JO - Giordania 8
PA - Panama 8
RO - Romania 8
UZ - Uzbekistan 8
MA - Marocco 6
PT - Portogallo 6
PY - Paraguay 6
TN - Tunisia 6
CR - Costa Rica 5
SK - Slovacchia (Repubblica Slovacca) 5
AU - Australia 4
BG - Bulgaria 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GR - Grecia 4
MY - Malesia 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
AL - Albania 3
BY - Bielorussia 3
CL - Cile 3
DZ - Algeria 3
HR - Croazia 3
KE - Kenya 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BT - Bhutan 2
DM - Dominica 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
ME - Montenegro 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
Totale 10.350
Salva come PNG Salva come JPEG
Città #
Singapore 782
Amsterdam 693
Ashburn 469
San Jose 348
Chandler 332
Los Angeles 188
New York 157
Frankfurt am Main 155
Rome 132
Beijing 114
Dublin 111
Hefei 105
Milan 99
Tokyo 81
Dallas 78
Ho Chi Minh City 77
Hong Kong 77
Hanoi 69
Jakarta 64
Lauterbourg 64
Tukwila 64
Munich 56
São Paulo 45
Boston 40
Helsinki 38
San Mateo 38
Santa Clara 37
Seoul 35
The Dalles 35
Marseille 33
Houston 32
Moscow 32
Atlanta 30
Warsaw 29
Boardman 28
Princeton 28
Council Bluffs 27
Kent 27
Chicago 26
Palermo 26
Nuremberg 25
Orem 25
Toronto 25
Buffalo 24
Denver 24
Poplar 23
Montreal 22
Stockholm 22
Brooklyn 21
Da Nang 20
Dearborn 20
Ann Arbor 19
Düsseldorf 19
Paris 19
Wilmington 19
Chennai 18
London 18
Mexico City 18
Bremen 17
San Francisco 16
Turku 16
Johannesburg 15
Nanjing 15
Cattolica 14
Nürnberg 14
Pune 14
Augusta 13
Brno 13
Falkenstein 13
Vienna 13
Ankara 12
Belo Horizonte 12
Brussels 12
Phoenix 12
Rio de Janeiro 12
Seattle 12
Shanghai 12
Abidjan 11
Kish 11
Lancaster 11
Washington 11
Bologna 10
Haiphong 10
Jacksonville 10
Lappeenranta 10
Manchester 10
Redwood City 10
Salamanca 10
Secaucus 10
Skopje 10
Baghdad 9
Bari 9
Guangzhou 9
Mumbai 9
Turin 9
Amman 8
City of London 8
Columbus 8
Menlo Park 8
Wroclaw 8
Totale 5.758
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 1.044
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 503
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 338
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 312
Assessing floppy infants: a new module 213
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 204
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 195
Developmental milestones in type I spinal muscular atrophy 191
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 170
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 168
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 162
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 158
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 157
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 156
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 156
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 155
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 153
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 150
Predominant distal muscle involvement in spinal muscular atrophy 149
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 145
Longitudinal natural history of type I spinal muscular atrophy: A critical review 144
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 143
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 143
Longitudinal assessments in discordant twins with SMA 142
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 140
Early treatment of type II SMA slows rate of progression of scoliosis 137
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 136
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 136
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 135
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 134
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 134
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 134
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 133
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 132
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 131
Nusinersen in type 0 spinal muscular atrophy: should we treat? 126
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 125
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 124
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 124
Developmental milestones in type I spinal muscular atrophy 119
Sleep disorders in spinal muscular atrophy 118
Revised upper limb module for spinal muscular atrophy: Development of a new module 115
Clinical Variability in Spinal Muscular Atrophy Type III. 115
An observational study of functional abilities in infants, children, and adults with type 1 SMA 114
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 114
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 112
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 109
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 108
Development of an academic disease registry for spinal muscular atrophy 108
Risdiplam in Type 1 Spinal Muscular Atrophy 105
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 105
An observational study of functional abilities in infants, children, and adults with type 1 SMA 101
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 99
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 99
Long term follow-up of scoliosis progression in type II SMA patients 97
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 95
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 94
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 92
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 90
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 84
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 80
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 78
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 77
Revised upper limb module for spinal muscular atrophy: 12 month changes 77
An observational study of functional abilities in infants, children, and adults with type 1 SMA 73
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 72
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 68
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 67
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 58
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Loss of ambulation in SMA III at the time of disease-modifying treatments: an international study 16
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 10
Development of the “SMA NNE,” a short neonatal neurological examination for newborns with spinal muscular atrophy 9
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 7
Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry 5
The phenotypic spectrum and genetic determinants of severe spinal muscular atrophy in individuals with a single SMN2 copy: an international retrospective observational study 4
Totale 10.490
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022385 0 6 5 72 28 11 9 63 26 19 73 73
2022/20231.150 99 150 66 162 76 144 70 104 164 19 55 41
2023/2024992 34 165 34 88 51 172 152 54 19 49 80 94
2024/20251.684 41 24 108 82 134 92 71 67 249 139 374 303
2025/20265.498 524 135 305 591 872 1.339 724 197 229 267 198 117
2026/2027282 211 71 0 0 0 0 0 0 0 0 0 0
Totale 10.490